Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells.
Resveratrol is a polyphenolic phytoestrogen that has been shown to exhibit potent anti-oxidant, anti-inflammatory, and anti-catabolic properties. Increased osteoclastic and decreased osteoblastic activities result in bone resorption and loss of bone mass. These changes have been implicated in pathological processes in rheumatoid arthritis and osteoporosis. Receptor activator of NF-κB ligand (RANKL), a member of the TNF superfamily, is a major mediator of bone loss. In this study, we investigated the effects of resveratrol on RANKL during bone morphogenesis in high density bone cultures in vitro. Untreated bone-derived cell cultures produced well organized bone-like structures with a bone-specific matrix. Treatment with RANKL induced formation of tartrate-resistant acid phosphatase-positive multinucleated cells that exhibited morphological features of osteoclasts. RANKL induced NF-κB activation, whereas pretreatment with resveratrol completely inhibited this activation and suppressed the activation of IκBα kinase and IκBα phosphorylation and degradation. RANKL up-regulated p300 (a histone acetyltransferase) expression, which, in turn, promoted acetylation of NF-κB. Resveratrol inhibited RANKL-induced acetylation and nuclear translocation of NF-κB in a time- and concentration-dependent manner. In addition, activation of Sirt-1 (a histone deacetylase) by resveratrol induced Sirt-1-p300 association in bone-derived and preosteoblastic cells, leading to deacetylation of RANKL-induced NF-κB, inhibition of NF-κB transcriptional activation, and osteoclastogenesis. Co-treatment with resveratrol activated the bone transcription factors Cbfa-1 and Sirt-1 and induced the formation of Sirt-1-Cbfa-1 complexes. Overall, these results demonstrate that resveratrol-activated Sirt-1 plays pivotal roles in regulating the balance between the osteoclastic versus osteoblastic activity result in bone formation in vitro thereby highlighting its therapeutic potential for treating osteoporosis and rheumatoid arthritis-related bone loss.
Institute of Anatomy, Ludwig-Maximilian-University Munich, Munich, Germany. mehdi.shakibaei@med.uni-muenchen.de
Mehdi
M
Shakibaei
Constanze
C
Buhrmann
Ali
A
Mobasheri
D000818:Animals; D001854:Bone Marrow Cells / Q000378:metabolism*; D002460:Cell Line; D050659:Core Binding Factor Alpha 1 Subunit / Q000235:genetics / Q000378:metabolism; D004285:Dogs; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D046912:Multiprotein Complexes / Q000235:genetics / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D010010:Osteoclasts / Q000378:metabolism*; D010024:Osteoporosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D053245:RANK Ligand / Q000378:metabolism*; D000077185:Resveratrol; D012213:Rheumatic Fever / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D056564:Sirtuin 1 / Q000378:metabolism*; D013267:Stilbenes / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects; D050880:p300-CBP Transcription Factors / Q000235:genetics / Q000378:metabolism*; D000099224:p300-CBP-Associated Factor
D050659:Core Binding Factor Alpha 1 Subunit; D004791:Enzyme Inhibitors; D046912:Multiprotein Complexes; D016328:NF-kappa B; D053245:RANK Ligand; D000077185:Resveratrol; D056564:Sirtuin 1; D013267:Stilbenes; D050880:p300-CBP Transcription Factors; D000099224:p300-CBP-Associated Factor
Nature. 2003 May 15;423(6937):337-42
12748652
EMBO J. 2000 Feb 15;19(4):662-71
10675335
Endocrinology. 2001 Mar;142(3):1290-5
11181547
Nat Rev Drug Discov. 2006 Jun;5(6):493-506
16732220
Cell. 1998 Apr 17;93(2):165-76
9568710
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5
10097072
Cell. 2002 Apr;109 Suppl:S81-96
11983155
Histol Histopathol. 1993 Jul;8(3):463-70
8358158
EMBO J. 1999 Nov 1;18(21):6106-18
10545121
J Immunol. 2000 Jun 15;164(12):6509-19
10843709
J Immunol. 1999 Jul 1;163(1):434-42
10384146
Ann N Y Acad Sci. 2004 Dec;1030:434-41
15659827
Biochem Pharmacol. 2008 Dec 1;76(11):1426-39
18606398
Bone. 1999 Jul;25(1):137-9
10423039
Oncogene. 2007 Aug 13;26(37):5489-504
17694089
Calcif Tissue Int. 1982 May;34(3):285-90
6809291
Nature. 1999 Jan 28;397(6717):315-23
9950424
Genes Dev. 1998 May 1;12(9):1260-8
9573043
Cell. 1997 Apr 18;89(2):309-19
9108485
Biochem Pharmacol. 2008 Feb 1;75(3):677-87
17959154
Oncogene. 1999 Nov 22;18(49):6938-47
10602468
Nature. 2003 Sep 11;425(6954):191-6
12939617
Mutat Res. 2003 Feb-Mar;523-524:145-50
12628512
Radiol Clin North Am. 2010 May;48(3):483-95
20609887
Microbiol Mol Biol Rev. 2000 Jun;64(2):435-59
10839822
Blood. 1991 Apr 15;77(8):1796-803
2015402
Dis Aquat Organ. 2004 May 5;59(2):171-4
15212284
Planta Med. 2004 Apr;70(4):305-9
15095144
Arthritis Res Ther. 2009;11(6):R165
19889203
Bone. 2006 Sep;39(3):542-51
16616712
Johns Hopkins Med J. 1979 Jul;145(1):10-24
376922
J Biol Chem. 2004 Sep 3;279(36):37219-22
15252035
Dev Dyn. 2000 Dec;219(4):461-71
11084646
Am J Pathol. 2001 Nov;159(5):1689-99
11696430
Cell. 1996 Nov 29;87(5):953-9
8945521
N Engl J Med. 1995 Feb 2;332(5):305-11
7816067
Genes Dev. 2004 Jan 1;18(1):12-6
14724176
J Bone Miner Res. 2003 Feb;18(2):270-7
12568404
Nat Med. 1997 Nov;3(11):1285-9
9359707
Science. 2001 Aug 31;293(5535):1653-7
11533489
Biochem J. 1999 Sep 15;342 Pt 3:615-23
10477272
Curr Opin Cell Biol. 2002 Dec;14(6):763-72
12473352
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602
9520411
Genes Dev. 1997 Dec 15;11(24):3482-96
9407039
Endocr Rev. 1992 Feb;13(1):66-80
1555533
Science. 1999 Apr 2;284(5411):143-7
10102814
Science. 2000 Sep 1;289(5484):1504-8
10968780
Am J Obstet Gynecol. 1995 Sep;173(3 Pt 2):982-9
7573295
Endocrinology. 1998 Jun;139(6):2659-61
9607769
Oral Dis. 2002 May;8(3):147-59
12108759
Ann N Y Acad Sci. 2007 Jan;1095:554-63
17404069
Nature. 1996 Sep 5;383(6595):22-3
8779707
J Bone Miner Res. 2002 Jul;17(7):1200-10
12096833
Exp Cell Res. 1998 Apr 10;240(1):95-106
9570925
J Biol Chem. 2010 Aug 13;285(33):25103-8
20501658
J Biol Chem. 1996 May 24;271(21):12511-6
8647859
Cell. 1997 Aug 22;90(4):595-606
9288740
Cell Cycle. 2005 Oct;4(10):1342-5
16123594
J Biol Chem. 2009 Sep 25;284(39):26533-46
19633292
J Cell Biochem. 2007 Aug 1;101(5):1266-77
17265428
Nature. 1996 Dec 19-26;384(6610):641-3
8967953
Carcinogenesis. 2001 Aug;22(8):1111-7
11470738